Member Info for volcano

we all could have done better but we still here
the shares i have traded when they were rock bottom.
TCG, FXPO,KAZ,PLUS,TW.
long term is a winner in the market not trading.
but yes you are right markets are overvalued and selling started already

Comment by Justin Ash, Chief Executive Officer

Â

"The current difficult market conditions - also seen by other operators - had a greater impact on our business in the seven months to 31 July 2018 than we had expected. Nevertheless, through this transitional period we are relentlessly focused on raising our clinical quality to "best in sector" level and we believe this is beginning to bear fruit as a commercial differentiator. The recent achievement of an "Outstanding" CQC result at Spire Nottingham means that Spire now has four "Outstanding" hospitals out of only 14 in the entire independent sector, and all other CQC hospital or service inspections this year have been upgrades to "Good".

Â

With our renewed focus on the private market, we are seeing encouraging momentum and expect our top line to recover through the second half of 2018 and increasingly in 2019 and beyond, while the benefit of our major cost savings initiatives will accelerate through next year.

Â

Our ongoing plans to lead on quality, to move our business model further towards the private payor and to adapt our operating costs to this new model, put us in a strong position against our competitors. We remain confident in our medium to long term prospects and fully committed to the delivery of our 80/100/200 Strategy."

Government intervene when banks were shorted in financial crisis, why they can' do it for the healthcare.

£400m pounds got wiped out in three days just like that , this is actually painful to watch. reminds me of the dot.com era.

you are getting bit personal there mate , i am not a shorter of SPI and i wouldn't know how to do it.
if you are loosing money do not blame me and stop calling me names .
where did i ever say sell SPI. show me that message please.

177p looks like base for today, but how low can it go?

Is Spire Healthcare Group (LON:SPI) a Buy or a Sell? Peel Hunt Place Shares Under Review

is it worth investing at 180p

Spire Healthcare Group PLC 45.8% Potential Upside Indicated by Numis
Posted by: Amilia Stone 7th August 2018

Spire Healthcare Group PLC using EPIC/TICKER code (LON:SPI) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Numis. Spire Healthcare Group PLC are listed in the Health Care sector within UK Main Market. Numis have set their target price at 280 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 45.8% from the opening price of 192.1 GBX. Over the last 30 and 90 trading days the company share price has decreased 60.5 points and decreased 33.9 points respectively. The 52 week high for the share price is currently at 340.1 GBX while the year low stock price is currently 150.2 GBX.

Spire Healthcare Group PLC has a 50 day moving average of 251.52 GBX and a 200 day moving average of 246.58. There are currently 401,081,376 shares in issue with the average daily volume traded being 1,457,444. Market capitalisation for LON:SPI is £759,480,136 GBP.

Company News yesterday

Spire slashes guidance but potential remains

Average volume 1.82m
Shares outstanding 401.08m
Free float 277.87m
P/E (TTM) 45.35
Market cap 779.52m GBP
EPS (TTM) 0.0419 GBP

Government has the power to stop this as they did for the Banks when they were in trouble.
They should do it for the rest of the industry .

Abzena technology used to enhance Faron Pharma cancer drug
07:24 08 Aug 2018
The company used its Composite Human Antibody platform to enhance the drug
clinical trial graphic
The work was carried out in the US with support from the company's UK operation
Abzena plc (LON:ABZA) has successfully manufactured a potential new cancer drug that incorporates the company’s Composite Human Antibody platform.

The ‘Abzena Inside’ technology was deployed to enhance Clevegen, a pre-clinical treatment being developed Faron Pharmaceuticals (LON:FARN).

Abzena said the manufacture of the new product took place at its site in San Diego, but used the bioanalytics and bioassay expertise of its Cambridge operation.

"We are pleased to have enabled the progression of an Abzena Inside antibody towards clinical development through this partnership,” said Jim Mills, head of technical operations.

“It really demonstrates the depth of our integrated services and technologies, showing how our sites work together to provide the support that our partners require to move their products forward from molecule design into clinical trials."

The company has a twin strategy: it provides support services for the bio-pharma industry and it grafts its technologies into drugs hoping to enhance efficacy.

The latter is the company’s ‘Abzena Inside’ strategy, which mirrors the approach taken by chipmaker Intel, which provides the processors that power millions of PCs and laptops worldwide.

used to be £7 a share few years ago , i should have stick with it.

Capita PLC (LON:CPI) had its Overweight rating reiterated by JPMorgan Chase & Co.
ByME Staff -August 7, 2018
Share on Facebook Tweet on Twitter
Analyst Ratings For Capita PLC (LON:CPI)

Today, JPMorgan Chase & Co. reiterated its Overweight rating on Capita PLC (LON:CPI).

There are 11 Hold Ratings, 5 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Capita PLC (LON:CPI) is Hold with a consensus target price of GBX 182.17 per share, a potential .

Some recent analyst ratings include

best day today for a long time

it is on the up now 318p

hell of a long tree shake , this is been going down now for a week .

Capita plc ("Capita" or the "Company") is pleased to announce that the 3 for 2 Rights Issue of 1,001,032,281 New Shares at 70 pence per New Share announced on 23 April 2018 closed for acceptances at 11.00 a.m. (London time) on 24 May 2018. The Company received valid acceptances in respect of 973,496,670 New Shares, representing approximately 97.25 per cent. of the total number of New Shares to be issued pursuant to the fully underwritten Rights Issue.

70p soon